Correction

Waldenström macroglobulinemia treatment algorithm 2018 (Blood Cancer Journal, (2018), 8, 4, (40), 10.1038/s41408-018-0076-5)

Research output: Contribution to journalComment/debate

Abstract

Following the publication of this article the authors noted that the sentence on page 5 reading “The major response rate was 80% with no difference between patients with wild-type or mutated MYD 88” was incorrect, and should read as “The major response rate was 80% with no difference between patients with mild-type or mutated CXCR4”. The authors wish to apologise for any inconvenience caused. This has now been corrected in the HTML and PDF.

Original languageEnglish (US)
Article number53
JournalBlood cancer journal
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Waldenstrom Macroglobulinemia
Publications
Reading
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{cf5d7573b14f46739fae483dc181b248,
title = "Correction: Waldenstr{\"o}m macroglobulinemia treatment algorithm 2018 (Blood Cancer Journal, (2018), 8, 4, (40), 10.1038/s41408-018-0076-5)",
abstract = "Following the publication of this article the authors noted that the sentence on page 5 reading “The major response rate was 80{\%} with no difference between patients with wild-type or mutated MYD 88” was incorrect, and should read as “The major response rate was 80{\%} with no difference between patients with mild-type or mutated CXCR4”. The authors wish to apologise for any inconvenience caused. This has now been corrected in the HTML and PDF.",
author = "Morie Gertz",
year = "2019",
month = "7",
day = "1",
doi = "10.1038/s41408-019-0212-x",
language = "English (US)",
volume = "9",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Correction

T2 - Waldenström macroglobulinemia treatment algorithm 2018 (Blood Cancer Journal, (2018), 8, 4, (40), 10.1038/s41408-018-0076-5)

AU - Gertz, Morie

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Following the publication of this article the authors noted that the sentence on page 5 reading “The major response rate was 80% with no difference between patients with wild-type or mutated MYD 88” was incorrect, and should read as “The major response rate was 80% with no difference between patients with mild-type or mutated CXCR4”. The authors wish to apologise for any inconvenience caused. This has now been corrected in the HTML and PDF.

AB - Following the publication of this article the authors noted that the sentence on page 5 reading “The major response rate was 80% with no difference between patients with wild-type or mutated MYD 88” was incorrect, and should read as “The major response rate was 80% with no difference between patients with mild-type or mutated CXCR4”. The authors wish to apologise for any inconvenience caused. This has now been corrected in the HTML and PDF.

UR - http://www.scopus.com/inward/record.url?scp=85067869901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067869901&partnerID=8YFLogxK

U2 - 10.1038/s41408-019-0212-x

DO - 10.1038/s41408-019-0212-x

M3 - Comment/debate

VL - 9

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 7

M1 - 53

ER -